{"id":503639,"date":"2020-08-24T07:44:01","date_gmt":"2020-08-24T07:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=503639"},"modified":"2020-08-24T07:44:01","modified_gmt":"2020-08-24T07:44:01","slug":"hemophilia-b-clinical-trial-insight-pipeline-assessment-companies-and-emerging-drugs-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-b-clinical-trial-insight-pipeline-assessment-companies-and-emerging-drugs-by-delveinsight_503639.html","title":{"rendered":"Hemophilia B Clinical Trial Insight, Pipeline Assessment, Companies and Emerging Drugs by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hemophilia B Clinical Trial Insight, Pipeline Assessment, Companies and Emerging Drugs by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Hemophilia B Clinical Trial Insight, Pipeline Assessment, Companies and Emerging Drugs by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Hemophilia B Pipeline Insight, 2020&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">(Albany, US) DelveInsight has launched a new report on<strong> &#8220;Hemophilia B Pipeline Insight, 2020&#8221;<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\" target=\"_blank\"><strong>Hemophilia B Pipeline Insight, 2020<\/strong><\/a>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Hemophilia B&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Hemophilia B&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Hemophilia B&nbsp;<\/strong>treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;<strong>Hemophilia B&nbsp;<\/strong>commercial assessment and clinical assessment of the&nbsp;<strong>Hemophilia B&nbsp;<\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;<strong>Hemophilia B&nbsp;<\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key companies covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novo Nordisk<\/li>\n<li>CSL Behring<\/li>\n<li>Bioverativ Therapeutics<\/li>\n<li>UniQure<\/li>\n<li>Pfizer<\/li>\n<li>Freeline Therapeutics<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rebinyn<\/li>\n<li>Idelvion<\/li>\n<li>Alprolix<\/li>\n<li>Etranacogene dezaparvovec (AMT-061)<\/li>\n<li>Fidanacogene elaparvovec<\/li>\n<li>FLT180a<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Report Highlights:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;<strong>Hemophilia B&nbsp;<\/strong>report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em><strong>Hemophilia B&nbsp;<\/strong>across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em><strong>Hemophilia B&nbsp;<\/strong><em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;<strong>Hemophilia B&nbsp;<\/strong><em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;<strong>Hemophilia B<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-market\">Hemophilia B<\/a><\/strong> is a genetic disorder caused by missing or defective Factor IX clotting protein.With the lack of this, the blood cannot clot properly to control bleeding like hemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.<\/p>\n<p style=\"text-align: justify;\">It is caused by an inherited X-linked recessive trait, with the defective gene located on the X chromosome. A male who has a hemophilia gene on his X chromosome will have hemophilia. When a female has a haemophilia gene on only one of her X chromosomes, she is a &#8220;hemophilia carrier&rdquo; and can pass the gene to her children.<\/p>\n<p style=\"text-align: justify;\">Sometimes carriers have low levels of clotting factor and have symptoms of hemophilia, including bleeding. Clotting factors are proteins in the blood that work together with platelets to stop or control bleeding.<\/p>\n<p style=\"text-align: justify;\">The main signs and symptoms of hemophilia are excessive bleeding and easy bruising. The child may suffer from recurrent nose bleeds, blood loss from small cuts, long-term bleeding in the mouth from bites, or after removal of a tooth, on-and-off bleeding from a cut or injury, bleeding within the skin or muscle and soft tissue that causes build-up of blood in the area.<\/p>\n<p style=\"text-align: justify;\">The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity. Identification of a hemizygous F9 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Report Introduction<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Hemophilia B&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">2.1. Overview<\/p>\n<p style=\"text-align: justify;\">2.2. History&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.3. Hemophilia B Symptoms<\/p>\n<p style=\"text-align: justify;\">2.4. Causes<\/p>\n<p style=\"text-align: justify;\">2.5.Pathophysiology<\/p>\n<p style=\"text-align: justify;\">2.6. Hemophilia B Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.6.1. Diagnostic Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>3. Hemophilia B&nbsp;Current Treatment Patterns<\/strong><\/p>\n<p style=\"text-align: justify;\">3.1. Hemophilia B Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\"><strong>4. Hemophilia B&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/strong><\/p>\n<p style=\"text-align: justify;\">4.1. In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">4.1.1. Hemophilia B&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">4.1.1.1. Assessment Summary<\/p>\n<p style=\"text-align: justify;\">4.1.2. Hemophilia B&nbsp;Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.3. Hemophilia B&nbsp;Acquisition Analysis<\/p>\n<p style=\"text-align: justify;\"><strong>5. Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.1.1. Assessment by Phase of Development<\/p>\n<p style=\"text-align: justify;\">5.1.2. Assessment by Product Type (Mono \/ Combination)<\/p>\n<p style=\"text-align: justify;\">5.1.2.1. Assessment by Stage and Product Type<\/p>\n<p style=\"text-align: justify;\">5.1.3. Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.3.1. Assessment by Stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.4. Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.4.1. Assessment by Stage and Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.5. Assessment by MOA<\/p>\n<p style=\"text-align: justify;\">5.1.5.1. Assessment by Stage and MOA<\/p>\n<p style=\"text-align: justify;\">5.1.6. Assessment by Target<\/p>\n<p style=\"text-align: justify;\">5.1.6.1. Assessment by Stage and Target<\/p>\n<p style=\"text-align: justify;\"><strong>6. Hemophilia B Late Stage Products (Phase-III)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Hemophilia B Mid Stage Products (Phase-II)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. Early Stage Products (Phase-I)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9. Pre-clinical Products and Discovery Stage Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Inactive Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Dormant Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Hemophilia B Discontinued Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. Hemophilia B&nbsp;Product Profiles<\/strong><\/p>\n<p style=\"text-align: justify;\">13.1. Drug Name: Company&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p style=\"text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p style=\"text-align: justify;\">13.1.2. Research and Development<\/p>\n<p style=\"text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p style=\"text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p style=\"text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p style=\"text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p style=\"text-align: justify;\">13.1.3.3. Acquisition&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p style=\"text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p style=\"text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"text-align: justify;\">Detailed information in the report?&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>14. Hemophilia B&nbsp;Key Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. Hemophilia B&nbsp;Key Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. Dormant and Discontinued Products<\/strong><\/p>\n<p style=\"text-align: justify;\">16.1. Dormant Products<\/p>\n<p style=\"text-align: justify;\">16.1.1. Reasons for being dormant<\/p>\n<p style=\"text-align: justify;\">16.2. Discontinued Products&nbsp;<\/p>\n<p style=\"text-align: justify;\">16.2.1. Reasons for the discontinuation<\/p>\n<p style=\"text-align: justify;\"><strong>17. Hemophilia B&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Hemophilia B&nbsp;Future Perspectives<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Hemophilia B&nbsp;Analyst Review&nbsp;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>21. Report Methodology<\/strong><\/p>\n<p style=\"text-align: justify;\">21.1. Secondary Research<\/p>\n<p style=\"text-align: justify;\">21.2. Expert Panel Validation<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC:<\/strong><strong>&nbsp;https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hemophilia-b-clinical-trial-insight-pipeline-assessment-companies-and-emerging-drugs-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hemophilia-b-clinical-trial-insight-pipeline-assessment-companies-and-emerging-drugs-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Hemophilia B Pipeline Insight, 2020&#8221; &nbsp; (Albany, US) DelveInsight has launched a new report on &#8220;Hemophilia B Pipeline Insight, 2020&#8221;. &nbsp; &#8220;Hemophilia B Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-b-clinical-trial-insight-pipeline-assessment-companies-and-emerging-drugs-by-delveinsight_503639.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-503639","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/503639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=503639"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/503639\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=503639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=503639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=503639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}